PE20201279A1 - Agente anticerigeno - Google Patents

Agente anticerigeno

Info

Publication number
PE20201279A1
PE20201279A1 PE2020000411A PE2020000411A PE20201279A1 PE 20201279 A1 PE20201279 A1 PE 20201279A1 PE 2020000411 A PE2020000411 A PE 2020000411A PE 2020000411 A PE2020000411 A PE 2020000411A PE 20201279 A1 PE20201279 A1 PE 20201279A1
Authority
PE
Peru
Prior art keywords
cyclized
anticancer agent
targeting peptide
tumor targeting
cysteine residues
Prior art date
Application number
PE2020000411A
Other languages
English (en)
Inventor
Carolyn Theresey Dillon
Judith Anne Carrall
Original Assignee
Univ Wollongong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017904199A external-priority patent/AU2017904199A0/en
Application filed by Univ Wollongong filed Critical Univ Wollongong
Publication of PE20201279A1 publication Critical patent/PE20201279A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/74—Aromatic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/74—Aromatic compounds
    • C07F9/76—Aromatic compounds containing hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/74—Aromatic compounds
    • C07F9/78—Aromatic compounds containing amino groups

Abstract

Referido a un agente anticancerigeno que comprende un peptido dirigido al tumor ciclado, de formula I, que tiene un atomo de arsenico unido a dos residuos de cisteina, que dichos residuos de cisteina estan separados por menos de 20 residuos de aminoacidos (linea curva); R es un grupo estabilizador unido al atomo de arsenico, en donde el grupo estabilizador se selecciona del grupo que consiste en hidroxilo, C1 a C6 alquilo, C2 a C6 alquenilo, arilo, etc. Dicho peptido dirigido al tumor ciclado comprende al menos un residuo de arginina o lisina. Tambien se refiere a una composicion farmaceutica, un proceso para producir dicho agente anticancerigeno y un metodo in vitro para el diagnostico del cancer.
PE2020000411A 2017-10-17 2018-10-17 Agente anticerigeno PE20201279A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017904199A AU2017904199A0 (en) 2017-10-17 Anti-cancer agent
PCT/AU2018/000202 WO2019075507A1 (en) 2017-10-17 2018-10-17 ANTICANCER AGENT

Publications (1)

Publication Number Publication Date
PE20201279A1 true PE20201279A1 (es) 2020-11-24

Family

ID=66172988

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000411A PE20201279A1 (es) 2017-10-17 2018-10-17 Agente anticerigeno

Country Status (16)

Country Link
US (1) US11819489B2 (es)
EP (1) EP3676282A4 (es)
JP (1) JP7345459B2 (es)
KR (1) KR20200071725A (es)
CN (1) CN111344298A (es)
AU (1) AU2018352461B2 (es)
BR (1) BR112020007145A2 (es)
CA (1) CA3075650A1 (es)
CL (1) CL2020001438A1 (es)
IL (1) IL272705B1 (es)
MX (1) MX2020002273A (es)
NZ (1) NZ761556A (es)
PE (1) PE20201279A1 (es)
SG (1) SG11202001669UA (es)
WO (1) WO2019075507A1 (es)
ZA (1) ZA202000996B (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60328513D1 (de) * 2002-11-07 2009-09-03 Newsouth Innovations Pty Ltd Induktion der mitochondrialen permeabilitätstransition
US20090110662A1 (en) 2007-04-30 2009-04-30 Intezyne Technologies, Inc. Modification of biological targeting groups for the treatment of cancer
CN101874034A (zh) * 2007-12-12 2010-10-27 Zio医药肿瘤学公司 用于治疗癌症的化合物和方法

Also Published As

Publication number Publication date
WO2019075507A9 (en) 2020-05-22
AU2018352461A1 (en) 2020-02-27
CN111344298A (zh) 2020-06-26
WO2019075507A1 (en) 2019-04-25
EP3676282A1 (en) 2020-07-08
AU2018352461B2 (en) 2020-07-16
EP3676282A4 (en) 2021-07-14
US11819489B2 (en) 2023-11-21
BR112020007145A2 (pt) 2020-09-24
SG11202001669UA (en) 2020-03-30
CA3075650A1 (en) 2019-04-25
KR20200071725A (ko) 2020-06-19
US20210205259A1 (en) 2021-07-08
ZA202000996B (en) 2022-07-27
JP7345459B2 (ja) 2023-09-15
MX2020002273A (es) 2020-09-21
NZ761556A (en) 2024-02-23
IL272705A (en) 2020-04-30
CL2020001438A1 (es) 2020-09-21
IL272705B1 (en) 2024-03-01
JP2021509394A (ja) 2021-03-25

Similar Documents

Publication Publication Date Title
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
EA201990221A1 (ru) 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов
CO2018000303A2 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
PE20190705A1 (es) COMPUESTOS DE BENZO[b] TIOFENO COMO AGONISTAS DE STING
BR112018070956A2 (pt) compostos da fórmula, composições farmacêuticas e métodos para distribuir um ácido nucleico para o fígado de um animal e para preparar um composto da fórmula
BR112018010650A2 (pt) pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal
BR112018015413A2 (pt) inibidores de indoleamina-2,3-dioxigenase (ido)
PE20181852A1 (es) Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
BR112017005760A2 (pt) conjugados e reagentes de conjugação
PE20171095A1 (es) Acidos grasos novedosos y su uso en la conjugacion con biomoleculas
CY1122074T1 (el) Νεα παραγωγα 3'-δεοξυαδενοσινης του φωσφοραμαδικου εστερα toy 2' και/η 5' aminoξεος ως αντικαρκινικες ενωσεις
EA201791535A1 (ru) Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение
BR112015004501A2 (pt) derivado de ácido hialurônico tendo aminoácidos e grupos esterila introduzidos no mesmo
EA201892745A1 (ru) Фосфорамидатные производные нуклеозида в качестве противораковых агентов
PE20191235A1 (es) Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente
BR112019001253A2 (pt) composto, composição farmacêutica, e, métodos de tratamento de câncer ou de atrofia muscular e de doença de parkinson.
BR112017018305A2 (pt) desacetoxitubulisina h e análogos da mesma
EA202090720A1 (ru) ПРОИЗВОДНЫЕ GalNAc
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
MX2018000239A (es) Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
CR20210127A (es) Molécula de unión al antigeno anti grupo de diferenciación 137 (cd137) y su uso
WO2016130800A3 (en) Pharmaceutical compositions comprising perillyl alcohol derivatives
EA201790788A1 (ru) Жидкая фармацевтическая композиция, содержащая пеметрексед